Table 2.
Acquired resistance to second-line injectable drugs and other predictors of death*
| Characteristic | Hazard Ratio | 95% Confidence Intervals | Age Adjusted Hazard Ratio | 95% Confidence Intervals |
|---|---|---|---|---|
|
| ||||
| AR to SLI (<8 months of treatment) | ||||
| Yes | 1.1 | 0.4 – 3.4 | 1.4 | 0.4 – 4.5 |
| No | Reference | Reference | ||
|
| ||||
| AR to SLI (>8 months of treatment) | ||||
| Yes | 2.4 | 1.3 – 4.7 | 2.8 | 1.4 – 5.4 |
| No | Reference | Reference | ||
|
| ||||
| Age groups | ||||
| 0 – 24 | 0.6 | 0.3 – 1.3 | ||
| 25 – 44 | 1.5 | 1.1 – 2.1 | N/A | N/A |
| 45 – 64 | Reference | |||
| > 64 | 3.5 | 2.4 – 5.1 | ||
|
| ||||
| Gender | ||||
| Male | 1.2 | 0.9 – 1.6 | 1.1 | 0.8 -1.5 |
| Female | Reference | Reference | ||
|
| ||||
| Illicit drugs use | ||||
| Yes | 1.6 | 1.1 – 2.3 | 2.0 | 1.4 – 2.9 |
| No | Reference | Reference | ||
|
| ||||
| HIV status | ||||
| Positive | 5.0 | 3.9 – 6.5 | 8.8 | 6.5 – 11.9 |
| Not positive | Reference | Reference | ||
|
| ||||
| MDR TB | ||||
| Yes | 1.3 | 1.0 – 1.8 | 1.6 | 1.2 – 2.1 |
| No | Reference | Reference | ||
|
| ||||
| Site of disease | ||||
| Any Extrapulmonary | 2.3 | 1.8 – 3.1 | 2.6 | 1.9 – 3.4 |
| Pulmonary only | Reference | Reference | ||
|
| ||||
| Initial regimen | ||||
| Any SLD | 1.5 | 1.1 – 2.0 | 1.7 | 1.2 – 2.2 |
| No SLD | Reference | Reference | ||
|
| ||||
| DOT | ||||
| Self-administrated | 2.8 | 2.1 – 3.7 | 2.5 | 1.9 – 3.4 |
| Directly observed | Reference | Reference | ||
Notes: AR: acquired resistance, SLI: second-line injectable drugs, N/A: not available, HIV: human immunodeficiency virus, MDR TB: multidrug-resistant tuberculosis, SLD: second-line drugs, DOT: Directly Observed Therapy.
*
Results received using Cox Proportional Hazard regression